mesalamine has been researched along with Proctitis in 82 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Proctitis: INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study showed that a daily bedtime dose of a 500 mg mesalamine suppository is safe and efficacious in children with ulcerative proctitis." | 9.14 | Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. ( Giguere, M; Heyman, MB; Kierkus, J; Shbaklo, H; Spénard, J, 2010) |
| "Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day." | 9.14 | Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. ( Andus, T; Baranovsky, A; Cascorbi, I; Dilger, K; Dorofeyev, AE; Greinwald, R; Kocjan, A; Lozynskyy, YS; Mikhailova, TL; Mohrbacher, R; Müser, M; Stolte, M; Vieth, M; Zvyagintseva, TD, 2010) |
| "To evaluate the effectiveness of metronidazole in combination with corticosteroids in enema and mesalazine (5-aminosalicylic acid) in comparison with the same protocol without metronidazole in the treatment of chronic radiation proctitis." | 9.09 | Metronidazole in the treatment of chronic radiation proctitis: clinical trial. ( Cavcić, J; Jelincić, Z; Martinac, P; Panijan-Pezerović, R; Turcić, J; Unusić, J; Zupancić, B, 2000) |
| "The therapeutic efficacy of 1 g 5-aminosalicylic acid enema was compared with that of 90 mg hydrocortisone acetate foam following daily rectal administration to patients with idiopathic proctitis or proctosigmoiditis during two weeks." | 9.07 | [5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial]. ( Ngô, Y; Rambaud, JC, 1992) |
| " We present a case of an 8-year-old female patient with intolerance to mesalamine and proctitis resistant to conventional therapy who responded to rectal tacrolimus treatment." | 7.80 | Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. ( Blasco-Alonso, J; Gallego-Gutiérrez, S; Girón Fernández-Crehuet, F; Luque Pérez, S; Navas-López, VM; Serrano Nieto, MJ; Sierra Salinas, C, 2014) |
| "Mesalamine was well tolerated." | 6.76 | A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. ( Lamet, M, 2011) |
| " There was no significant difference between treatments in adverse events, and both groups had an overall drug compliance of greater than 95%." | 6.71 | Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. ( Dallaire, C; de Montigny, D; Grace, M; Lamet, M; Ptak, T; Shah, U; Spenard, J, 2005) |
| "Marks score or the ulcerative colitis disease-activity index) at two and four weeks." | 6.71 | Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. ( Berlanga-Acosta, J; Nightingale, J; Playford, RJ; Sinha, A; West, KP, 2003) |
| "This study showed that a daily bedtime dose of a 500 mg mesalamine suppository is safe and efficacious in children with ulcerative proctitis." | 5.14 | Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. ( Giguere, M; Heyman, MB; Kierkus, J; Shbaklo, H; Spénard, J, 2010) |
| "Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day." | 5.14 | Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. ( Andus, T; Baranovsky, A; Cascorbi, I; Dilger, K; Dorofeyev, AE; Greinwald, R; Kocjan, A; Lozynskyy, YS; Mikhailova, TL; Mohrbacher, R; Müser, M; Stolte, M; Vieth, M; Zvyagintseva, TD, 2010) |
| "To evaluate the effectiveness of metronidazole in combination with corticosteroids in enema and mesalazine (5-aminosalicylic acid) in comparison with the same protocol without metronidazole in the treatment of chronic radiation proctitis." | 5.09 | Metronidazole in the treatment of chronic radiation proctitis: clinical trial. ( Cavcić, J; Jelincić, Z; Martinac, P; Panijan-Pezerović, R; Turcić, J; Unusić, J; Zupancić, B, 2000) |
| "The therapeutic efficacy of 1 g 5-aminosalicylic acid enema was compared with that of 90 mg hydrocortisone acetate foam following daily rectal administration to patients with idiopathic proctitis or proctosigmoiditis during two weeks." | 5.07 | [5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial]. ( Ngô, Y; Rambaud, JC, 1992) |
| " We present a case of an 8-year-old female patient with intolerance to mesalamine and proctitis resistant to conventional therapy who responded to rectal tacrolimus treatment." | 3.80 | Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. ( Blasco-Alonso, J; Gallego-Gutiérrez, S; Girón Fernández-Crehuet, F; Luque Pérez, S; Navas-López, VM; Serrano Nieto, MJ; Sierra Salinas, C, 2014) |
| "Mesalazine, betamethasone, and misoprostol are the best topical agents for radiation proctitis and formalin has an inflammatory effect and should not be used." | 3.73 | Histopathological comparison of topical therapy modalities for acute radiation proctitis in an experimental rat model. ( Aksoy, M; Asoglu, O; Bilge, H; Kapran, Y; Kiremit-Korkut, N; Korkut, C; Parlak, M, 2006) |
| " She had been diagnosed 2 months before as having ulcerative proctitis and was treated with mesalamine, which induced a full remission, but 3 antibiotic regimens failed to improve her lung disease." | 3.70 | [Mesalamine-induced hypersensitivity pneumonitis]. ( Fireman, Z; Weiner, P; Weizman, J; Zamir, C; Zamir, D, 1999) |
| "Proctitis is the least extensive type of ulcerative colitis, for which rectal therapy is rarely studied and is underused." | 3.11 | Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial. ( Abdulkhakov, S; Abrahamovych, O; Alexeeva, O; Andreev, P; Baluta, M; Datsenko, O; Delmans, G; Dorofeyev, A; Greinwald, R; Kharchenko, N; Khimion, L; Kolesnik, IP; Kruis, W; Lesniakowski, K; Levchenko, O; Maksyashina, SV; Mihaly, E; Mohrbacher, R; Mostovoy, Y; Mueller, R; Pokrotnieks, J; Sablin, OA; Siegmund, B; Simanenkov, V; Sobon, M; Uspenskiy, Y; Viacheslav, N; Vieth, M, 2022) |
| "Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms." | 2.90 | Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. ( Abdulkhakov, S; Alekseeva, O; Andreev, P; Datsenko, O; Dorofeyev, AE; Greinwald, R; Kruis, W; Levchenko, O; Lozynskyy, Y; Mohrbacher, R; Mostovoy, Y; Neshta, V; Pesegova, M; Siegmund, B; Soloviev, K; Stiess, M; Vieth, M, 2019) |
| " The frequency of adverse events was comparable between groups, regardless of baseline 5-ASA use." | 2.82 | Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. ( Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ, 2016) |
| "Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease." | 2.82 | Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. ( Caron, B; Danese, S; Hart, A; Panaccione, R; Peyrin-Biroulet, L; Sandborn, WJ; Schreiber, S; Solitano, V, 2022) |
| "Marks score or the ulcerative colitis disease-activity index) at two and four weeks." | 2.71 | Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. ( Berlanga-Acosta, J; Nightingale, J; Playford, RJ; Sinha, A; West, KP, 2003) |
| " The dose-response relationship was statistically significant (p = 0." | 2.69 | Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. ( Bianchi Porro, G; Campieri, M; d'Albasio, G; Miglioli, M; Paoluzi, P; Pera, A; Prantera, C; Sturniolo, GC, 1998) |
| "Thirty-eight patients with distal ulcerative colitis (n = 17) or ulcerative proctitis (n = 21) in clinical, endoscopic, and histologic remission were randomly assigned to receive either oral mesalazine (0." | 2.67 | Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. ( Hatzis, A; Mantzaris, GJ; Petraki, K; Spiliadi, C; Triantaphyllou, G, 1994) |
| "Thirty patients with distal ulcerative colitis in remission (17 proctitis, 13 proctosigmoiditis) were randomly given either 5-aminosalicylic acid (5-ASA) or placebo suppositories, 400 mg bid." | 2.67 | 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. ( Boscaino, A; D'Arienzo, A; D'Armiento, FP; Giannattasio, F; Lancia, C; Mazzacca, G; Panarese, A; Quattrone, P, 1990) |
| "Conventional therapies for ulcerative colitis and Crohn's disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti-tumor necrosis factor agents." | 2.47 | Conventional medical management of inflammatory bowel disease. ( Burger, D; Travis, S, 2011) |
| "Optimizing treatment goals in ulcerative colitis requires recognizing the needs of patients." | 2.46 | Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine. ( Elkjaer, M; Marteau, P; Michetti, P; Munkholm, P; Probert, CS, 2010) |
| " Mesalamine enema dosing intervals between QHS to Q3 days maintained efficacy." | 2.41 | A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. ( Cohen, RD; Hanauer, SB; Thisted, RA; Woseth, DM, 2000) |
| "An increase incidence of ulcerative colitis (UC) has been reported in Mexico." | 1.51 | Ulcerative colitis: epidemiology, clinical features and associated factors with surgical treatment in a tertiary hospital in Mexico. ( Alarcón-Bernés, L; Gracida-Mancilla, NI; Jiménez-Bobadilla, B; León-Rendón, JL; López-Pérez, RY; Villanueva Herrero, JA, 2019) |
| "Linear IgA bullous dermatosis is a rare bullous disease in children and adults that can be associated with autoimmune conditions, malignancies, infections, or medication exposure." | 1.48 | Linear IgA bullous dermatosis associated with ulcerative proctitis: treatment challenge. ( Burns, C; Yetto, T, 2018) |
| "Whether the epidemiology of ulcerative colitis (UC) has changed during recent decades is partly unknown." | 1.46 | Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. ( Cao, Y; Eriksson, C; Halfvarson, J; Henriksson, I; Montgomery, S; Rundquist, S; Zhulina, Y, 2017) |
| "Although some ulcerative colitis (UC) patients are diagnosed when they do not have any UC-related symptoms, clinical features and prognosis of UC diagnosed in asymptomatic patients remain unclear." | 1.40 | Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. ( Byeon, JS; Jung, KW; Kim, J; Kim, JH; Kim, JW; Kim, KJ; Kim, SO; Myung, SJ; Park, SH; Park, SK; Yang, DH; Yang, SK; Ye, BD, 2014) |
| "Topical treatment in proctitis patients was underused in Switzerland." | 1.40 | Topical therapy is underused in patients with ulcerative colitis. ( Beglinger, C; Fournier, N; Mottet, C; Pittet, V; Rogler, G; Seibold, F, 2014) |
| "Radiation proctitis is a common complication of pelvic radiation for which an optimal treatment remains undetermined." | 1.37 | The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis. ( Joo, HR; Kim, TG; Kim, TO; Moon, YS; Park, J; Park, MJ; Park, SH; Ryu, DY; Seo, EH; Song, GA; Yang, SY, 2011) |
| "Radiation proctitis is a well-known complication of abdominal and pelvic radiation." | 1.28 | Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis. ( Baum, CA; Biddle, WL; Miner, PB, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (9.76) | 18.7374 |
| 1990's | 16 (19.51) | 18.2507 |
| 2000's | 17 (20.73) | 29.6817 |
| 2010's | 32 (39.02) | 24.3611 |
| 2020's | 9 (10.98) | 2.80 |
| Authors | Studies |
|---|---|
| Nunes, VRT | 1 |
| Vidigal, PVT | 1 |
| Pereira, MT | 1 |
| Ladeira, LCD | 1 |
| Caliari, MV | 1 |
| Oliveira, FMS | 1 |
| Cesar, ALA | 1 |
| Faraco, AAG | 1 |
| Barbuto, RC | 1 |
| Duval-Araujo, I | 1 |
| Caron, B | 4 |
| Sandborn, WJ | 3 |
| Panaccione, R | 2 |
| Schreiber, S | 2 |
| Hart, A | 1 |
| Solitano, V | 1 |
| Danese, S | 3 |
| Peyrin-Biroulet, L | 3 |
| Kruis, W | 2 |
| Siegmund, B | 2 |
| Lesniakowski, K | 1 |
| Simanenkov, V | 1 |
| Khimion, L | 1 |
| Sobon, M | 1 |
| Delmans, G | 1 |
| Maksyashina, SV | 1 |
| Sablin, OA | 1 |
| Pokrotnieks, J | 1 |
| Mostovoy, Y | 2 |
| Datsenko, O | 2 |
| Abdulkhakov, S | 2 |
| Dorofeyev, A | 1 |
| Levchenko, O | 2 |
| Alexeeva, O | 1 |
| Andreev, P | 2 |
| Kolesnik, IP | 1 |
| Mihaly, E | 1 |
| Abrahamovych, O | 1 |
| Baluta, M | 1 |
| Kharchenko, N | 1 |
| Viacheslav, N | 1 |
| Uspenskiy, Y | 1 |
| Vieth, M | 3 |
| Mohrbacher, R | 3 |
| Mueller, R | 1 |
| Greinwald, R | 4 |
| Aruljothy, A | 1 |
| Singh, S | 1 |
| Narula, N | 1 |
| Moran, GW | 1 |
| Vuyyuru, SK | 1 |
| Hogan, M | 1 |
| Zayadi, A | 1 |
| MacDonald, JK | 1 |
| Peyrin Biroulet, L | 1 |
| Ma, C | 1 |
| Jairath, V | 1 |
| Lie, MRKL | 1 |
| Kreijne, JE | 1 |
| Dijkstra, G | 1 |
| Löwenberg, M | 1 |
| van Assche, G | 1 |
| West, RL | 1 |
| van Noord, D | 1 |
| van der Meulen-de Jong, AE | 1 |
| Oldenburg, B | 1 |
| Zaal, RJ | 1 |
| Hansen, BE | 1 |
| de Vries, AC | 1 |
| Janneke van der Woude, C | 1 |
| Dubois, E | 1 |
| Moens, A | 1 |
| Geelen, R | 1 |
| Sabino, J | 1 |
| Ferrante, M | 1 |
| Vermeire, S | 1 |
| Ungar, B | 1 |
| Kopylov, U | 2 |
| Harbord, M | 1 |
| Eliakim, R | 1 |
| Bettenworth, D | 1 |
| Karmiris, K | 1 |
| Katsanos, K | 1 |
| Kucharzik, T | 1 |
| Molnár, T | 1 |
| Raine, T | 1 |
| Sebastian, S | 1 |
| de Sousa, HT | 1 |
| Dignass, A | 1 |
| Carbonnel, F | 1 |
| Eriksson, C | 1 |
| Cao, Y | 1 |
| Rundquist, S | 1 |
| Zhulina, Y | 1 |
| Henriksson, I | 1 |
| Montgomery, S | 1 |
| Halfvarson, J | 1 |
| Cuomo, A | 1 |
| Sgambato, D | 1 |
| D'Auria, MV | 1 |
| Miranda, A | 1 |
| Ferrante, E | 1 |
| Romano, M | 1 |
| Kato, S | 1 |
| Ishibashi, A | 1 |
| Kani, K | 1 |
| Yakabi, K | 1 |
| Neshta, V | 1 |
| Pesegova, M | 1 |
| Alekseeva, O | 1 |
| Lozynskyy, Y | 1 |
| Soloviev, K | 1 |
| Dorofeyev, AE | 2 |
| Stiess, M | 1 |
| Liu, Z | 1 |
| Huang, S | 1 |
| Chen, Z | 1 |
| Wang, X | 1 |
| Yetto, T | 1 |
| Burns, C | 1 |
| León-Rendón, JL | 1 |
| Jiménez-Bobadilla, B | 1 |
| López-Pérez, RY | 1 |
| Gracida-Mancilla, NI | 1 |
| Alarcón-Bernés, L | 1 |
| Villanueva Herrero, JA | 1 |
| Seibold, F | 1 |
| Fournier, N | 1 |
| Beglinger, C | 1 |
| Mottet, C | 1 |
| Pittet, V | 1 |
| Rogler, G | 1 |
| Watanabe, M | 1 |
| Nishino, H | 1 |
| Sameshima, Y | 1 |
| Ota, A | 1 |
| Nakamura, S | 1 |
| Hibi, T | 1 |
| Andersson, P | 1 |
| Norblad, R | 1 |
| Söderholm, JD | 1 |
| Myrelid, P | 1 |
| Park, SK | 1 |
| Ye, BD | 1 |
| Yang, SK | 1 |
| Kim, SO | 1 |
| Kim, J | 1 |
| Kim, JW | 2 |
| Park, SH | 2 |
| Yang, DH | 1 |
| Jung, KW | 1 |
| Kim, KJ | 1 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Kim, JH | 1 |
| Gecse, KB | 1 |
| Lakatos, PL | 2 |
| Actis, GC | 1 |
| Pellicano, R | 1 |
| Rosina, F | 1 |
| Hernández Martínez, A | 1 |
| Lázaro Sáez, M | 1 |
| Bendezú García, RA | 1 |
| Patrón Román, GO | 1 |
| Kaye, TL | 1 |
| O'Connor, A | 1 |
| Burke, D | 1 |
| Tolan, DJ | 1 |
| Yamamoto, T | 2 |
| Shimoyama, T | 2 |
| Matsumoto, K | 2 |
| Navas-López, VM | 1 |
| Blasco-Alonso, J | 1 |
| Girón Fernández-Crehuet, F | 1 |
| Serrano Nieto, MJ | 1 |
| Gallego-Gutiérrez, S | 1 |
| Luque Pérez, S | 1 |
| Sierra Salinas, C | 1 |
| Sun, S | 1 |
| Cavey, T | 1 |
| Peltier, L | 1 |
| Bendavid, C | 1 |
| Bouguen, G | 1 |
| Bosworth, BP | 1 |
| Rubin, DT | 1 |
| Harper, JR | 1 |
| Cortot, A | 1 |
| Maetz, D | 1 |
| Degoutte, E | 1 |
| Delette, O | 1 |
| Meunier, P | 1 |
| Tan, G | 1 |
| Cazals, JB | 1 |
| Dewit, O | 1 |
| Hebuterne, X | 1 |
| Beorchia, S | 1 |
| Grunberg, B | 1 |
| Leprince, E | 1 |
| D'Haens, G | 1 |
| Forestier, S | 1 |
| Idier, I | 1 |
| Lémann, M | 1 |
| Bernal-Sprekelsen, JC | 1 |
| de las Marinas, MD | 1 |
| Salvador, A | 1 |
| Landete, FJ | 1 |
| Morera, FJ | 1 |
| Andus, T | 1 |
| Kocjan, A | 1 |
| Müser, M | 1 |
| Baranovsky, A | 1 |
| Mikhailova, TL | 1 |
| Zvyagintseva, TD | 1 |
| Lozynskyy, YS | 1 |
| Cascorbi, I | 1 |
| Stolte, M | 1 |
| Dilger, K | 1 |
| Munkholm, P | 1 |
| Michetti, P | 1 |
| Probert, CS | 1 |
| Elkjaer, M | 1 |
| Marteau, P | 3 |
| Lamet, M | 2 |
| Heyman, MB | 1 |
| Kierkus, J | 1 |
| Spénard, J | 2 |
| Shbaklo, H | 1 |
| Giguere, M | 1 |
| Seo, EH | 1 |
| Kim, TO | 1 |
| Kim, TG | 1 |
| Joo, HR | 1 |
| Park, J | 1 |
| Yang, SY | 1 |
| Moon, YS | 1 |
| Park, MJ | 1 |
| Ryu, DY | 1 |
| Song, GA | 1 |
| Burger, D | 1 |
| Travis, S | 1 |
| Richter, JM | 1 |
| Kushkuley, S | 1 |
| Barrett, JA | 1 |
| Oster, G | 1 |
| Criscuoli, V | 1 |
| Rizzuto, MR | 1 |
| Cottone, M | 1 |
| Domènech, E | 1 |
| Gisbert, JP | 1 |
| Zembrzuska, H | 1 |
| Ally, MR | 1 |
| Goldberg, ME | 1 |
| Watson, J | 1 |
| Veerappan, GR | 1 |
| Horwhat, JD | 1 |
| Herberhold, C | 1 |
| Folwaczny, C | 1 |
| Sanguineti, G | 1 |
| Franzone, P | 1 |
| Marcenaro, M | 1 |
| Foppiano, F | 1 |
| Vitale, V | 1 |
| Sinha, A | 1 |
| Nightingale, J | 1 |
| West, KP | 1 |
| Berlanga-Acosta, J | 1 |
| Playford, RJ | 1 |
| Farrell, RJ | 1 |
| Ptak, T | 1 |
| Dallaire, C | 1 |
| Shah, U | 1 |
| Grace, M | 1 |
| de Montigny, D | 1 |
| Kane, S | 1 |
| Seo, GS | 1 |
| Choi, SC | 1 |
| Jo, EY | 1 |
| Choi, CS | 1 |
| Kim, TH | 1 |
| Yun, KJ | 1 |
| Nah, YH | 1 |
| Korkut, C | 1 |
| Asoglu, O | 1 |
| Aksoy, M | 1 |
| Kapran, Y | 1 |
| Bilge, H | 1 |
| Kiremit-Korkut, N | 1 |
| Parlak, M | 1 |
| Regueiro, M | 2 |
| Loftus, EV | 2 |
| Steinhart, AH | 2 |
| Cohen, RD | 3 |
| Lakatos, L | 1 |
| Guslandi, M | 1 |
| Giollo, P | 1 |
| Testoni, PA | 1 |
| Declerck, D | 1 |
| Wallaert, B | 1 |
| Demarcq-Delerue, G | 1 |
| Tonnel, AB | 1 |
| Mantzaris, GJ | 1 |
| Hatzis, A | 1 |
| Petraki, K | 1 |
| Spiliadi, C | 1 |
| Triantaphyllou, G | 1 |
| Lucidarme, D | 1 |
| Foucault, M | 1 |
| Vautrin, B | 1 |
| Filoche, B | 1 |
| Gionchetti, P | 2 |
| Rizzello, F | 2 |
| Venturi, A | 2 |
| Ferretti, M | 2 |
| Brignola, C | 2 |
| Miglioli, M | 2 |
| Campieri, M | 4 |
| d'Albasio, G | 1 |
| Paoluzi, P | 1 |
| Bianchi Porro, G | 3 |
| Pera, A | 2 |
| Prantera, C | 1 |
| Sturniolo, GC | 2 |
| Peruzzo, S | 1 |
| Simmonds, NJ | 1 |
| Millar, AD | 1 |
| Blake, DR | 1 |
| Rampton, DS | 1 |
| Florent, C | 1 |
| Ardizzone, S | 1 |
| Doldo, P | 1 |
| Ranzi, T | 2 |
| Giglio, LA | 1 |
| Annese, V | 1 |
| D'Arienzo, A | 2 |
| Gaia, E | 1 |
| Gullini, S | 1 |
| Riegler, G | 1 |
| Valentini, M | 1 |
| Massa, P | 1 |
| Del Piano, M | 1 |
| Rossini, F | 1 |
| Guidetti, CS | 1 |
| Woseth, DM | 1 |
| Thisted, RA | 1 |
| Hanauer, SB | 1 |
| Zamir, D | 1 |
| Weizman, J | 1 |
| Zamir, C | 1 |
| Fireman, Z | 1 |
| Weiner, P | 1 |
| Cavcić, J | 1 |
| Turcić, J | 1 |
| Martinac, P | 1 |
| Jelincić, Z | 1 |
| Zupancić, B | 1 |
| Panijan-Pezerović, R | 1 |
| Unusić, J | 1 |
| Venkatesh, KS | 1 |
| Ramanujam, P | 1 |
| Ngô, Y | 1 |
| Rambaud, JC | 1 |
| Chapman, NJ | 1 |
| Brown, ML | 1 |
| Phillips, SF | 1 |
| Tremaine, WJ | 1 |
| Schroeder, KW | 1 |
| Dewanjee, MK | 1 |
| Zinsmeister, AR | 1 |
| Hadjigogos, K | 1 |
| Panarese, A | 1 |
| D'Armiento, FP | 1 |
| Lancia, C | 1 |
| Quattrone, P | 1 |
| Giannattasio, F | 1 |
| Boscaino, A | 1 |
| Mazzacca, G | 1 |
| De Franchis, R | 1 |
| Brunetti, G | 1 |
| Barbara, L | 1 |
| Tytgat, GN | 1 |
| Fockens, P | 1 |
| Schotborgh, RH | 1 |
| Hofer, SO | 1 |
| Triantafillidis, JK | 1 |
| Dadioti, P | 1 |
| Nicolakis, D | 1 |
| Mericas, E | 1 |
| Nelis, GF | 1 |
| Baum, CA | 1 |
| Biddle, WL | 1 |
| Miner, PB | 1 |
| van Hogezand, RA | 1 |
| van Hees, PA | 1 |
| van Gorp, JP | 1 |
| van Lier, HJ | 1 |
| Bakker, JH | 1 |
| Wesseling, P | 1 |
| van Haelst, UJ | 1 |
| van Tongeren, JH | 1 |
| Freund, U | 1 |
| Schölmerich, J | 1 |
| Siems, H | 1 |
| Kluge, F | 1 |
| Schäfer, HE | 1 |
| Wannenmacher, M | 1 |
| Sutherland, LR | 2 |
| Martin, F | 2 |
| Williams, CN | 1 |
| Haber, G | 1 |
| Aquino, JA | 1 |
| Greer, S | 1 |
| Robinson, M | 1 |
| Greenberger, N | 1 |
| Saibil, F | 1 |
| Martin, T | 1 |
| Sparr, J | 1 |
| Prokipchuk, E | 1 |
| Borgen, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.[NCT04165265] | 28 participants (Anticipated) | Interventional | 2019-12-03 | Recruiting | |||
| Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis[NCT01966783] | Phase 2 | 320 participants (Anticipated) | Interventional | 2013-09-30 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulc[NCT01008410] | Phase 3 | 265 participants (Actual) | Interventional | 2009-11-17 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulc[NCT01008423] | Phase 3 | 281 participants (Actual) | Interventional | 2009-11-20 | Completed | ||
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy[NCT00969111] | 70 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT01368055] | 361 participants (Actual) | Interventional | 2011-09-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 52.6 |
| Placebo | 37.9 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices:stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 46.6 |
| Placebo | 28.0 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Bowel frequency (BF) subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal disease and 3 indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 41.4 |
| Placebo | 25.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscale ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease, 2 = moderate disease and 3 = severe disease (spontaneous bleeding, ulceration). Percentage of participants with normal or mild disease have been presented in this outcome measure. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 55.6 |
| Placebo | 43.2 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Physician global assessment (PGA) subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 45.9 |
| Placebo | 30.3 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscore ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 57.1 |
| Placebo | 47.7 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 70.7 |
| Placebo | 53.0 |
Remission was a combined assessment of clinical and endoscopic variables, defined as an endoscopy score of less than or equal to (<=) 1, a rectal bleeding score of 0, and an improvement or no change from baseline in stool frequency subscales of the Modified Mayo Disease Activity Index (MMDAI) at the end of 6 weeks of treatment. MMDAI was used to assess the overall disease activity for each participant. MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment (PGA) and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Stool frequency MMDAI subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Endoscopy MMDAI subscore ranged from 0-3, where 0 indicated normal or inactive disease and 3 indicated severe disease (spontaneous bleeding, ulceration). (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 38.3 |
| Placebo | 25.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Baseline, Week 6
| Intervention | unit on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bowel frequency score: Baseline | Bowel frequency score: Change at Week 6 | Rectal Bleeding score:Baseline | Rectal Bleeding score: Change at Week 6 | PGA score:Baseline | PGA score: Change at Week 6 | Endoscopy score:Baseline | Endoscopy score: Change at Week 6 | Total score:Baseline | Total score: Change at Week 6 | |
| Budesonide | 1.8 | -0.7 | 2.1 | -1.2 | 1.8 | -0.8 | 2.1 | -0.8 | 7.8 | -3.5 |
| Placebo | 1.9 | -0.5 | 2.1 | -0.8 | 1.8 | -0.5 | 2.1 | -0.5 | 7.9 | -2.4 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Percentage of participants who were rectal bleeding responder at scheduled assessments were reported. Rectal bleeding responders were defined as those participants who achieved a rectal bleeding MMDAI subscale score of 0 during the treatment period. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Weeks 1, 2, 4, and 6
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Responder at 1 Assessment | Responder at 2 Assessment | Responder at 3 Assessment | Responder at 4 Assessment | |
| Budesonide | 12.0 | 18.8 | 21.1 | 6.0 |
| Placebo | 13.6 | 13.6 | 10.6 | 1.5 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 53.7 |
| Placebo | 34.0 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices:stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 50.0 |
| Placebo | 28.6 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal disease and 3 indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 46.3 |
| Placebo | 23.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscale ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease, 2 = moderate disease and 3 = severe disease (spontaneous bleeding, ulceration). Percentage of participants with normal or mild disease have been presented in this outcome measure. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 56.0 |
| Placebo | 36.7 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 49.3 |
| Placebo | 28.6 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscore ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 57.5 |
| Placebo | 38.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 72.4 |
| Placebo | 56.5 |
Remission was a combined assessment of clinical and endoscopic variables, defined as an endoscopy score of less than or equal to (<=) 1, a rectal bleeding score of 0, and an improvement or no change from baseline in stool frequency subscales of the Modified Mayo Disease Activity Index (MMDAI) at the end of 6 weeks of treatment. MMDAI was used to assess the overall disease activity for each participant. MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment (PGA) and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Stool frequency MMDAI subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Endoscopy MMDAI subscore ranged from 0-3, where 0 indicated normal or inactive disease and 3 indicated severe disease (spontaneous bleeding, ulceration). (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 44.0 |
| Placebo | 22.4 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Baseline, Week 6
| Intervention | unit on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bowel frequency score: Baseline | Bowel frequency score: Change at Week 6 | Rectal Bleeding score:Baseline | Rectal Bleeding score: Change at Week 6 | PGA score:Baseline | PGA score: Change at Week 6 | Endoscopy score:Baseline | Endoscopy score: Change at Week 6 | Total score:Baseline | Total score: Change at Week 6 | |
| Budesonide | 1.7 | -0.8 | 2.1 | -1.3 | 2.0 | -0.9 | 2.1 | -0.9 | 7.9 | -3.8 |
| Placebo | 1.8 | -0.5 | 2.1 | -0.9 | 2.0 | -0.6 | 2.1 | -0.5 | 8.0 | -2.5 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Percentage of participants who were rectal bleeding responder at scheduled assessments were reported. Rectal bleeding responders were defined as those participants who achieved a rectal bleeding MMDAI subscale score of 0 during the treatment period. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Weeks 1, 2, 4, and 6
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Responder at 1 assessment | Responder at 2 assessment | Responder at 3 assessment | Responder at 4 assessment | |
| Budesonide | 8.2 | 16.4 | 21.6 | 13.4 |
| Placebo | 18.4 | 17.0 | 7.5 | 2.0 |
12 reviews available for mesalamine and Proctitis
| Article | Year |
|---|---|
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Observation | 2022 |
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerativ | 2023 |
Drug development for ulcerative proctitis: current concepts.
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Ant | 2021 |
Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Consensus; Di | 2018 |
Ulcerative proctitis: an update on the pharmacotherapy and management.
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Disease Management; Humans; Mesalamine; Prednisolone; | 2014 |
A young woman with recurrent perianal sepsis.
Topics: Abscess; Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Drainage; Female; Humans; Ma | 2015 |
Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Health Care Costs; Humans; Mesalamine; | 2010 |
Conventional medical management of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroid | 2011 |
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, | 2006 |
Ulcerative proctitis: a review of pharmacotherapy and management.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Controlled Clini | 2008 |
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Glucocorticoids; Humans; Mesalamine; P | 2000 |
Proctitis.
Topics: Aminosalicylic Acids; Barium Sulfate; Crohn Disease; Diagnosis, Differential; Enema; Humans; Mesalam | 1990 |
29 trials available for mesalamine and Proctitis
| Article | Year |
|---|---|
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Topics: Budesonide; Colitis, Ulcerative; Double-Blind Method; Humans; Mesalamine; Proctitis; Quality of Life | 2022 |
No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Beclomethasone; Colitis, Ulcerative; Female; Humans; Male; | 2020 |
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Double-Blind Met | 2019 |
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Colitis, Ulcerative; | 2013 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-St | 2008 |
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administ | 2010 |
A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Mesalamine; Middle | 2011 |
Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Colitis, Ulcerative; F | 2010 |
Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
Topics: Acute Disease; Aged; Aged, 80 and over; Contraindications; Data Interpretation, Statistical; Dose Fr | 2003 |
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Bl | 2003 |
Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study.
Topics: Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Sche | 2005 |
Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis | 1994 |
Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis.
Topics: Acute Disease; Administration, Topical; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti- | 1997 |
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
Topics: Administration, Oral; Administration, Rectal; Adult; Colitis, Ulcerative; Female; Humans; Male; Mesa | 1998 |
Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; | 1998 |
Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Female; Humans; Male; | 1997 |
Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Drug Administration Sch | 2000 |
Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cross- | 1999 |
Metronidazole in the treatment of chronic radiation proctitis: clinical trial.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Beta | 2000 |
Metronidazole in the treatment of chronic radiation proctitis: clinical trial.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Beta | 2000 |
Metronidazole in the treatment of chronic radiation proctitis: clinical trial.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Beta | 2000 |
Metronidazole in the treatment of chronic radiation proctitis: clinical trial.
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Beta | 2000 |
[5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Enema; Female; Humans; Hydrocortis | 1992 |
5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
Topics: Administration, Rectal; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Drug | 1990 |
Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.
Topics: Adult; Aminosalicylic Acids; Colitis; Double-Blind Method; Female; Humans; Male; Mesalamine; Multice | 1990 |
Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.
Topics: Adult; Aminosalicylic Acids; Double-Blind Method; Female; Humans; Male; Mesalamine; Proctitis; Suppo | 1988 |
Mesalamine for ulcerative colitis.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Dose-Response Relationship, Dru | 1988 |
[Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy].
Topics: Aged; Aged, 80 and over; Aminosalicylic Acids; Clinical Trials as Topic; Double-Blind Method; Humans | 1987 |
5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada.
Topics: Adult; Aminosalicylic Acids; Canada; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Met | 1987 |
Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.
Topics: Administration, Rectal; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Double-Blind Method; | 1987 |
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.
Topics: Adult; Aminosalicylic Acids; Colitis; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; | 1987 |
41 other studies available for mesalamine and Proctitis
| Article | Year |
|---|---|
Evaluation of mesalazine polymeric conjugate in the treatment of actinic proctitis in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; | 2021 |
Ulcerative proctitis: Challenges for clinical management.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Proctitis | 2023 |
Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biological Factors; Colitis, Ulcerative; Drug Resista | 2020 |
Long-term outcome of ulcerative proctitis.
Topics: Cohort Studies; Colitis, Ulcerative; Humans; Mesalamine; Proctitis; Referral and Consultation | 2020 |
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulce | 2017 |
Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010.
Topics: Adolescent; Adult; Cohort Studies; Colectomy; Colitis, Ulcerative; Disease Progression; Female; Huma | 2017 |
Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis.
Topics: Adolescent; Adult; Aged; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Middle Aged; Proctit | 2018 |
Effects of mesalazine enemas on lymphoid follicular proctitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colonoscopy; Endoscopy, Gastrointestinal; Enema; Hum | 2018 |
Linear IgA bullous dermatosis associated with ulcerative proctitis: treatment challenge.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Immu | 2018 |
Ulcerative colitis: epidemiology, clinical features and associated factors with surgical treatment in a tertiary hospital in Mexico.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Incidence | 2019 |
Topical therapy is underused in patients with ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adolescent; Adrenal Cortex Ho | 2014 |
Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis--a single institution experience.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adolescent; Adrenal Cortex Hormones; Adult; Anastomosis, Surgic | 2014 |
Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Diseases | 2014 |
Ulcerative proctitis in out-patient practice: an unexpected clinical challenge.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Beclometha | 2014 |
[Chemical proctitis due to ergotamine: «not always an ulcerative colitis»].
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differ | 2015 |
Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; E | 2015 |
Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Female; | 2014 |
Letter: wide variation in faecal calprotectin values according to the assay.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Leukocyte L1 Antigen C | 2016 |
Letter: wide variation in faecal calprotectin values according to the assay - authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Leukocyte L1 Antigen C | 2016 |
Recurrent pericarditis in a patient with ulcerative proctitis due to mesalazine suppositories.
Topics: Humans; Male; Mesalamine; Middle Aged; Pericarditis; Proctitis; Radiography, Thoracic; Recurrence; S | 2010 |
The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female | 2011 |
Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2012 |
A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cytomegalovirus Infections; Humans; Lymphomatoid Pap | 2012 |
Letter: real-life management of new onset ulcerative colitis and proctitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Glucocorticoids; Humans; Male; | 2012 |
Treatment of intractable rectal stump drainage with cryoablation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blast Injuries; Buttocks; Colostomy; Cryosurgery; Ex | 2012 |
Ulcerating proctitis in a patient with congenital neutropenia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Fissure in Ano; Humans; Male; Mesalamine; Neutropeni | 2003 |
Epidermal growth factor for ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Therapy, Co | 2003 |
Is non-adherence to blame?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalami | 2005 |
[The usefulness of mesalazine suppositories for the treatment of lymphoid follicular proctitis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Mesalamine; Middle Aged; | 2006 |
Histopathological comparison of topical therapy modalities for acute radiation proctitis in an experimental rat model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Betamethasone; Diseas | 2006 |
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
Topics: Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; D | 2006 |
A combination of rectal beclomethasone diproprionate and mesalazine in ulcerative proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Beclomethasone; Drug Therapy, | 2008 |
[Iatrogenic diffuse interstitial pneumonia linked to 5-aminosalicylate].
Topics: Aminosalicylic Acids; Colitis; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Human | 1994 |
Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agen | 1999 |
[Mesalamine-induced hypersensitivity pneumonitis].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug H | 1999 |
Endoscopic therapy for radiation proctitis-induced hemorrhage in patients with prostatic carcinoma using argon plasma coagulator application.
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Aged; Aged, 80 and over; Anti | 2002 |
Distribution of mesalamine enemas in patients with active distal ulcerative colitis.
Topics: Adolescent; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Colon, Sigmoid; Enema; Female; Humans; | 1992 |
Unusual side effects of mesalazine.
Topics: Adult; Alopecia; Aminosalicylic Acids; Female; Humans; Mesalamine; Proctitis | 1991 |
High doses of 5-aminosalicylic acid enemas in chronic radiation proctitis: comparison with betamethasone enemas.
Topics: Adult; Aged; Aminosalicylic Acids; Betamethasone; Chronic Disease; Enema; Female; Humans; Mesalamine | 1990 |
Diarrhoea due to 5-aminosalicylic acid in breast milk.
Topics: Adult; Aminosalicylic Acids; Breast Feeding; Diarrhea, Infantile; Female; Humans; Infant; Mesalamine | 1989 |
Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis.
Topics: Aminosalicylic Acids; Chronic Disease; Drug Evaluation; Enema; Female; Humans; Male; Mesalamine; Pro | 1989 |